Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary
- PMID: 36534462
- PMCID: PMC9770023
- DOI: 10.2196/39141
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary
Abstract
Background: The Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is one of Europe's oldest sentinel systems, working with the UK Health Security Agency (UKHSA) and its predecessor bodies for 55 years. Its surveillance report now runs twice weekly, supplemented by online observatories. In addition to conducting sentinel surveillance from a nationally representative group of practices, the RSC is now also providing data for syndromic surveillance.
Objective: The aim of this study was to describe the cohort profile at the start of the 2021-2022 surveillance season and recent changes to our surveillance practice.
Methods: The RSC's pseudonymized primary care data, linked to hospital and other data, are held in the Oxford-RCGP Clinical Informatics Digital Hub, a Trusted Research Environment. We describe the RSC's cohort profile as of September 2021, divided into a Primary Care Sentinel Cohort (PCSC)-collecting virological and serological specimens-and a larger group of syndromic surveillance general practices (SSGPs). We report changes to our sampling strategy that brings the RSC into alignment with European Centre for Disease Control guidance and then compare our cohort's sociodemographic characteristics with Office for National Statistics data. We further describe influenza and COVID-19 vaccine coverage for the 2020-2021 season (week 40 of 2020 to week 39 of 2021), with the latter differentiated by vaccine brand. Finally, we report COVID-19-related outcomes in terms of hospitalization, intensive care unit (ICU) admission, and death.
Results: As a response to COVID-19, the RSC grew from just over 500 PCSC practices in 2019 to 1879 practices in 2021 (PCSC, n=938; SSGP, n=1203). This represents 28.6% of English general practices and 30.59% (17,299,780/56,550,136) of the population. In the reporting period, the PCSC collected >8000 virology and >23,000 serology samples. The RSC population was broadly representative of the national population in terms of age, gender, ethnicity, National Health Service Region, socioeconomic status, obesity, and smoking habit. The RSC captured vaccine coverage data for influenza (n=5.4 million) and COVID-19, reporting dose one (n=11.9 million), two (n=11 million), and three (n=0.4 million) for the latter as well as brand-specific uptake data (AstraZeneca vaccine, n=11.6 million; Pfizer, n=10.8 million; and Moderna, n=0.7 million). The median (IQR) number of COVID-19 hospitalizations and ICU admissions was 1181 (559-1559) and 115 (50-174) per week, respectively.
Conclusions: The RSC is broadly representative of the national population; its PCSC is geographically representative and its SSGPs are newly supporting UKHSA syndromic surveillance efforts. The network captures vaccine coverage and has expanded from reporting primary care attendances to providing data on onward hospital outcomes and deaths. The challenge remains to increase virological and serological sampling to monitor the effectiveness and waning of all vaccines available in a timely manner.
Keywords: COVID-19; cohort; cohort profile; computerized medical record systems; digital surveillance; general practice; health data; hospital; immunology; influenza; monitoring; outcome; primary care data; public health; representation; sampling; sentinel surveillance; serology; surveillance; syndromic surveillance; uptake; vaccination; virology; virus.
©Meredith Leston, William H Elson, Conall Watson, Anissa Lakhani, Carole Aspden, Clare R Bankhead, Ray Borrow, Elizabeth Button, Rachel Byford, Alex J Elliot, Xuejuan Fan, Uy Hoang, Ezra Linley, Jack Macartney, Brian D Nicholson, Cecilia Okusi, Mary Ramsay, Gillian Smith, Sue Smith, Mark Thomas, Dan Todkill, Ruby SM Tsang, William Victor, Alice J Williams, John Williams, Maria Zambon, Gary Howsam, Gayatri Amirthalingam, Jamie Lopez-Bernal, F D Richard Hobbs, Simon de Lusignan. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 19.12.2022.
Conflict of interest statement
Conflicts of Interest: As specified above, ML’s doctorate is partly funded by EMIS Health. MZ is a member of SAGE/NERVTAG/JCVI working/expert groups (unpaid positions) and chair of the charitable organization ISIRV (unpaid position). The Vaccine Evaluation Unit carries out contract research on behalf of UKHSA for GSK, Pfizer, and Sanofi. This is not directly related to the work in this publication. The Immunisation Department provides vaccine manufacturers (including Pfizer) with postmarketing surveillance reports about pneumococcal and meningococcal disease, which the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. FDRH has also received occasional fees or expenses for speaking or consultancy on cardiovascular disease from AstraZeneca, BI, Bayer, BMS/Pfizer, and Novartis. SdL is the director of the RCGP-RSC; he has received vaccine-related research funding from AstraZeneca, GSK, Sanofi, Seqirus, and Takeda, and has been a member of advisory boards for AstraZeneca, Sanofi, and Seqirus. The other authors have no conflicts of interest to declare.
Figures






Similar articles
-
Developing a digital phenotype to subdivide adult immunosuppressed COVID-19 outcomes within the English Primary Care Sentinel Network.Front Immunol. 2024 Dec 4;15:1491565. doi: 10.3389/fimmu.2024.1491565. eCollection 2024. Front Immunol. 2024. PMID: 39697345 Free PMC article.
-
Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024.JMIR Public Health Surveill. 2024 Apr 3;10:e52047. doi: 10.2196/52047. JMIR Public Health Surveill. 2024. PMID: 38569175 Free PMC article.
-
Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021.JMIR Public Health Surveill. 2021 Feb 19;7(2):e24341. doi: 10.2196/24341. JMIR Public Health Surveill. 2021. PMID: 33605892 Free PMC article.
-
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort.JMIR Public Health Surveill. 2024 May 24;10:e39297. doi: 10.2196/39297. JMIR Public Health Surveill. 2024. PMID: 38787605 Free PMC article.
-
Co-Administration of Influenza and COVID-19 Vaccines: Policy Review and Vaccination Coverage Trends in the European Union, UK, US, and Canada between 2019 and 2023.Vaccines (Basel). 2024 Feb 19;12(2):216. doi: 10.3390/vaccines12020216. Vaccines (Basel). 2024. PMID: 38400199 Free PMC article. Review.
Cited by
-
Developing a digital phenotype to subdivide adult immunosuppressed COVID-19 outcomes within the English Primary Care Sentinel Network.Front Immunol. 2024 Dec 4;15:1491565. doi: 10.3389/fimmu.2024.1491565. eCollection 2024. Front Immunol. 2024. PMID: 39697345 Free PMC article.
-
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population.Nephrol Dial Transplant. 2024 Dec 20;40(1):71-82. doi: 10.1093/ndt/gfae071. Nephrol Dial Transplant. 2024. PMID: 38520170 Free PMC article.
-
Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.J Med Internet Res. 2024 Aug 26;26:e56042. doi: 10.2196/56042. J Med Internet Res. 2024. PMID: 39186368 Free PMC article.
-
Modifiable risk factors for asthma exacerbations during the COVID-19 pandemic: a population-based repeated cross-sectional study using the Research and Surveillance Centre primary care database.Lancet Reg Health Eur. 2024 May 24;42:100938. doi: 10.1016/j.lanepe.2024.100938. eCollection 2024 Jul. Lancet Reg Health Eur. 2024. PMID: 38846423 Free PMC article.
-
Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales.Lancet Reg Health Eur. 2023 Dec 12;37:100816. doi: 10.1016/j.lanepe.2023.100816. eCollection 2024 Feb. Lancet Reg Health Eur. 2023. PMID: 38162515 Free PMC article.
References
-
- de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017 Oct;67(663):440–441. doi: 10.3399/bjgp17X692645. https://bjgp.org/cgi/pmidlookup?view=long&pmid=28963401 67/663/440 - DOI - PMC - PubMed
-
- Elliot AJ, Fleming DM. Surveillance of influenza-like illness in England and Wales during 1966-2006. Euro Surveill. 2006;11(10):249–250.651 - PubMed
-
- de Lusignan S, Tsang RSM, Amirthalingam G, Akinyemi O, Sherlock J, Tripathy M, Deeks A, Ferreira F, Howsam G, Hobbs FDR, Joy M. Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20. Lancet Reg Health Eur. 2021 Mar;2:100029. doi: 10.1016/j.lanepe.2021.100029. https://linkinghub.elsevier.com/retrieve/pii/S2666-7762(21)00006-5 S2666-7762(21)00006-5 - DOI - PMC - PubMed
-
- Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, Williams J, Button E, Campbell H, Sinnathamby M, Victor W, Anand S, Linley E, Hewson J, DArchangelo S, Otter AD, Ellis J, Hobbs RFD, Howsam G, Zambon M, Ramsay M, Brown KE, de Lusignan S, Amirthalingam G, Lopez Bernal J. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022 May;84(5):675–683. doi: 10.1016/j.jinf.2021.12.044. https://europepmc.org/abstract/MED/34990709 S0163-4453(21)00664-2 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials